A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
NCT ID: NCT03898791
Last Updated: 2021-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
48 participants
INTERVENTIONAL
2019-07-16
2021-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
NCT02735980
Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)
NCT05856695
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
NCT05361395
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
NCT06497530
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
NCT04262856
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LY3295668 Erbumine Cohort A
LY3295668 erbumine administered orally.
LY3295668 Erbumine
oral capsules
LY3295668 Erbumine Cohort B
LY3295668 erbumine administered orally.
LY3295668 Erbumine
oral capsules
LY3295668 Part JP
LY3295668 erbumine administered orally.
LY3295668 Erbumine
oral capsules
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LY3295668 Erbumine
oral capsules
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have adequate organ function.
* Have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.
* Have discontinued previous treatments for cancer.
* Are able to swallow capsules.
Exclusion Criteria
* Have a serious concomitant systemic disorder.
* Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C.
* Have a significant cardiac condition.
* Have previously received an aurora kinase inhibitor.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Highlands Oncology Group
Fayetteville, Arkansas, United States
Rocky Mountain Cancer Center
Denver, Colorado, United States
H Lee Moffitt Cancer Center
Tampa, Florida, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Washington University Medical School
St Louis, Missouri, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Levine Cancer Institute- Carolinas Medical Center
Charlotte, North Carolina, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Prisma Health Cancer Institute
Greenville, South Carolina, United States
Texas Oncology Cancer Center
Austin, Texas, United States
Texas Oncology Fort Worth
Fort Worth, Texas, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
US Oncology
The Woodlands, Texas, United States
Tyler Cancer Center
Tyler, Texas, United States
Grand Hopital de Charleroi-Site Notre-Dame
Charleroi, , Belgium
Universitair Ziekenhuis Gent
Ghent, , Belgium
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, , Belgium
AZ Delta
Roeselare, , Belgium
Institut Bergonie
Bordeaux, , France
Centre Georges Francois Leclerc
Dijon, , France
Centre de Lutte Contre le Cancer Leon Berard
Lyon, , France
APHM Hôpital de la Timone
Marseille, , France
Institut Curie
Paris, , France
Institut de Cancérologie de l'Ouest Centre René Gauducheau
Saint-Herblain, , France
National Cancer Center Hospital
Chuo-Ku, Tokyo, Japan
Severance Hospital Yonsei University Health System
Seoul, Korea, South Korea
Samsung Medical Center
Seoul, Korea, South Korea
Asan Medical Center
Seoul, , South Korea
Hospital Clinico Universitario Virgen de la Victoria
Málaga, Andalusia, Spain
Institut Catala d'Oncologia
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Universitario Ramon y Cajal
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario La Fe de Valencia
Valencia, , Spain
Dr.Abdurrahman Yurtaslan Ankara Oncology Training & Res Hosp
Ankara, , Turkey (Türkiye)
Ege University Faculty of Medicine
Izmir, , Turkey (Türkiye)
Guys/St. Thomas Hospital
London, Surrey, United Kingdom
Royal Marsden Hospital
Sutton, Surrey, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J1O-MC-JZHB
Identifier Type: OTHER
Identifier Source: secondary_id
2018-003485-14
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
17248
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.